Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

Status:	Completed
Conditions:	Angina, Angina
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - 85
Updated:	8/26/2018
Start Date:	November 23, 2015
End Date:	April 13, 2017

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina

A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with
stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise
time during an exercise treadmill test.

Inclusion Criteria

- History of chronic stable angina or at least 3 months prior to screening, with at
least 1 angina episode per month

- Ischemic heart disease documented by myocardial infarction, coronary angiography or a
revascularization procedure

- Receiving stable doses of cardiac medication

- Completes 2 exercise treadmill tests during screening meeting protocol requirements

Exclusion Criteria:

- Participating in another investigational study

- Current or prior malignancy within 5 years of randomization

- Known sensitivity to any components of the investigational product

- Not able to complete all protocol required study visits

- Having the following within 3 months prior to or during screening: Unstable angina or
acute coronary syndrome, transient Ischemic attack (TIA) or stroke, revascularization
procedure, or instability in ST-segment depression between screening exercise
treadmill tests, as assessed by the core electrocardiograph (ECG) laboratory

We found this trial at

sites

Clinical Trial Facility in Atlanta Georgia

Atlanta, Georgia

from

Atlanta, GA